Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
New Concepts Relating Mesenchymal Tumors Based on Genetics and Epigenetics
share announcement

New Concepts Relating Mesenchymal Tumors Based on Genetics and Epigenetics

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Microenvironment".

Deadline for manuscript submissions: 20 March 2026 | Viewed by 4021

Special Issue Editor

Dr. Uta Flucke

E-Mail Website
Guest Editor
1. Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
2. Diagnostic Laboratory, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
Interests: mesenchymal tumors; soft tissue; sarcoma; genetics; epigenetics

Special Issue Information

Dear Colleagues,

With the rapid development of new molecular techniques, we are able to reappraise our conventional classification system of soft tissue tumors, at least for certain tumor groups. Moreover, we are responsible for the development of new concepts.

A new classification mainly based on molecular findings may help treat patients better and collect adequate data of larger cohorts to understand the underlying biology and improve the therapy and assessment of prognosis.

In this Special Issue, we discuss categories of tumors, often selected in small groups based on clinicopathological findings, including immunohistochemistry, and wish to demonstrate that it would be useful to re-classify them due to the same genetic pathways and epigenetic findings leading to a more proper classification with clinical implications.

Dr. Uta Flucke
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mesenchymal tumors
  • soft tissue
  • sarcoma
  • genetics
  • epigenetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

20 pages, 785 KiB  
Review
Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma
by Vincenzo Ingangi, Annarosaria De Chiara, Gerardo Ferrara, Michele Gallo, Antonio Catapano, Flavio Fazioli, Gioconda Di Carluccio, Elisa Peranzoni, Ilaria Marigo, Maria Vincenza Carriero and Michele Minopoli
Cells 2024, 13(11), 977; https://doi.org/10.3390/cells13110977 - 4 Jun 2024
Cited by 6 | Viewed by 2069
Abstract
Chondrosarcoma (ChS), a malignant cartilage-producing tumor, is the second most frequently diagnosed osseous sarcoma after osteosarcoma. It represents a very heterogeneous group of malignant chemo- and radiation-resistant neoplasms, accounting for approximately 20% of all bone sarcomas. The majority of ChS patients have a [...] Read more.
Chondrosarcoma (ChS), a malignant cartilage-producing tumor, is the second most frequently diagnosed osseous sarcoma after osteosarcoma. It represents a very heterogeneous group of malignant chemo- and radiation-resistant neoplasms, accounting for approximately 20% of all bone sarcomas. The majority of ChS patients have a good prognosis after a complete surgical resection, as these tumors grow slowly and rarely metastasize. Conversely, patients with inoperable disease, due to the tumor location, size, or metastases, represent a great clinical challenge. Despite several genetic and epigenetic alterations that have been described in distinct ChS subtypes, very few therapeutic options are currently available for ChS patients. Therefore, new prognostic factors for tumor progression as well as new treatment options have to be explored, especially for patients with unresectable or metastatic disease. Recent studies have shown that a correlation between immune infiltrate composition, tumor aggressiveness, and survival does exist in ChS patients. In addition, the intra-tumor microvessel density has been proven to be associated with aggressive clinical behavior and a high metastatic potential in ChS. This review will provide an insight into the ChS microenvironment, since immunotherapy and antiangiogenic agents are emerging as interesting therapeutic options for ChS patients. Full article
(This article belongs to the Special Issue New Concepts Relating Mesenchymal Tumors Based on Genetics and Epigenetics)
►▼ Show Figures

Figure 1

Other

Jump to: Review

10 pages, 885 KiB  
Perspective
The Role of Epithelial–Mesenchymal Transition in Malignant Pleural Mesothelioma: From Pathogenesis to Diagnosis and Treatment
by Dimitrios E. Magouliotis, Fabrizio Minervini, Ugo Cioffi, Matilde De Simone, Davide Patrini and Marco Scarci
Cells 2025, 14(8), 585; https://doi.org/10.3390/cells14080585 - 12 Apr 2025
Viewed by 443
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive cancer of the pleural lining, primarily associated with asbestos exposure. Despite advancements in multimodal treatment, patient survival remains poor. Epithelial–mesenchymal transition (EMT) has emerged as a crucial process driving MPM pathogenesis, metastasis, and resistance to therapy. [...] Read more.
Malignant pleural mesothelioma (MPM) is an aggressive cancer of the pleural lining, primarily associated with asbestos exposure. Despite advancements in multimodal treatment, patient survival remains poor. Epithelial–mesenchymal transition (EMT) has emerged as a crucial process driving MPM pathogenesis, metastasis, and resistance to therapy. This review explores the molecular mechanisms underlying EMT in MPM, including key signaling pathways such as TGF-β, Wnt/β-catenin, and PI3K/Akt. We also discuss the diagnostic and prognostic significance of EMT-related biomarkers and emerging targeted therapies aimed at reversing EMT or exploiting EMT-induced vulnerabilities. Additionally, recent clinical trials, including the MARS 2 trial, are reviewed to provide insight into the evolving treatment landscape. Full article
(This article belongs to the Special Issue New Concepts Relating Mesenchymal Tumors Based on Genetics and Epigenetics)
►▼ Show Figures

Figure 1

11 pages, 1011 KiB  
Perspective
GLI1-Rearranged Enteric Tumors: Updates on Clinicopathologic and Molecular Genetics Features
by Ahmed I. Younes and Haider A. Mejbel
Cells 2025, 14(2), 118; https://doi.org/10.3390/cells14020118 - 14 Jan 2025
Viewed by 987
Abstract
Recent advances in molecular genetics, particularly in identifying and characterizing genetic abnormalities within mesenchymal neoplasms, have led to a more comprehensive and evolving classification system. Modern technological developments in cytogenetics and next-generation sequencing have enabled the analysis of small clinical samples, expanded our [...] Read more.
Recent advances in molecular genetics, particularly in identifying and characterizing genetic abnormalities within mesenchymal neoplasms, have led to a more comprehensive and evolving classification system. Modern technological developments in cytogenetics and next-generation sequencing have enabled the analysis of small clinical samples, expanded our understanding of tumor biology, and improved the diagnostic, prognostic, and predictive precision by identifying targeted genetic alterations, confirming the presence of fusion transcripts, and/or revealing the overexpression of specific genes and their targets. In this review, we focus specifically on the GLI1-rearranged enteric tumor, a recent clinicopathological entity that has emerged within the expanding classification of mesenchymal tumors. Herein, we aim to explore the histopathological features, molecular genetic characteristics, and clinical outcomes in these tumors. Due to their rarity and the extensive overlapping in their histopathological and molecular features with other neoplasms, continued research and systematic documentation of GLI1-rearranged enteric tumors is necessary to better understand their biological behavior, develop more accurate prognostic indicators, and establish optimal treatment strategies. Full article
(This article belongs to the Special Issue New Concepts Relating Mesenchymal Tumors Based on Genetics and Epigenetics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop